Brochure
18 Oct 2024
Daewoong Pharmaceutical Brochure
PDF 16.7 MB
Content provided by our supplier
Daewoong Pharmaceutical Co.,Ltd
-
Country/Region:Korea, Republic Of
-
On CPHI since:2015
-
Employees:1000 - 4999
Company types
Primary activities
Other Content from Daewoong Pharmaceutical Co.,Ltd (2)
-
Brochure Daewoong Bio Bioplant Promotion Brochure
It contains an overall introduction to Daewoong Bio's bio plant's milestones, manufacturing facilities, and production capacity. -
Video DAEWOONG PR VIDEO (EN)
We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.